Inhibition of Corneal Neovascularization by Subconjunctival Injection of Fc-Endostatin, a Novel Inhibitor of Angiogenesis

Stroke Rates after Introduction of Vascular Endothelial Growth Factor Inhibitors for Macular Degeneration: A Time Series Analysis

(2012) Robert J. Campbell et al.   OPHTHALMOLOGY

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

(2012) Daniel F. Martin et al.   OPHTHALMOLOGY

Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice

(2012) Xingqun Ma et al.   PLoS One

Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition

(2012) S. B. Sunshine et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Treatments for Corneal Neovascularization: A Review

(2011) Deepak Gupta et al.   CORNEA

Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin

(2011) Rachel Grossman et al.   JOURNAL OF NEUROSURGERY

Stroke and Anti-VEGF Therapy

(2011) Takashi Ueta et al.   OPHTHALMOLOGY

Endostatin specifically targets both tumor blood vessels and lymphatic vessels

(2011) Wei Zhuo et al.   Frontiers of Medicine

Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in their Antitumor Profiles

(2010) Kashi Javaherian et al.   Dose-Response

Corneal Neovascularization as a Risk Factor for Graft Failure and Rejection after Keratoplasty

(2010) Bjorn Bachmann et al.   OPHTHALMOLOGY

A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration

(2009) David S. Boyer et al.   OPHTHALMOLOGY

Linking Antibody Fc Domain to Endostatin Significantly Improves Endostatin Half-life and Efficacy

(2008) T.-Y. Lee et al.   CLINICAL CANCER RESEARCH